JP2023546536A5 - - Google Patents

Info

Publication number
JP2023546536A5
JP2023546536A5 JP2023547328A JP2023547328A JP2023546536A5 JP 2023546536 A5 JP2023546536 A5 JP 2023546536A5 JP 2023547328 A JP2023547328 A JP 2023547328A JP 2023547328 A JP2023547328 A JP 2023547328A JP 2023546536 A5 JP2023546536 A5 JP 2023546536A5
Authority
JP
Japan
Prior art keywords
use according
pharmaceutical composition
dose
fibrosis
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023547328A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023546536A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/054713 external-priority patent/WO2022081661A1/en
Publication of JP2023546536A publication Critical patent/JP2023546536A/ja
Publication of JP2023546536A5 publication Critical patent/JP2023546536A5/ja
Pending legal-status Critical Current

Links

JP2023547328A 2020-10-13 2021-10-13 線維症を処置する方法 Pending JP2023546536A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063091128P 2020-10-13 2020-10-13
US63/091,128 2020-10-13
PCT/US2021/054713 WO2022081661A1 (en) 2020-10-13 2021-10-13 Methods of treating fibrosis

Publications (2)

Publication Number Publication Date
JP2023546536A JP2023546536A (ja) 2023-11-02
JP2023546536A5 true JP2023546536A5 (enExample) 2024-11-14

Family

ID=81209448

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023547328A Pending JP2023546536A (ja) 2020-10-13 2021-10-13 線維症を処置する方法

Country Status (8)

Country Link
US (4) US11628167B2 (enExample)
EP (1) EP4229828A4 (enExample)
JP (1) JP2023546536A (enExample)
KR (1) KR20230107568A (enExample)
CN (1) CN116349204A (enExample)
AU (1) AU2021360767A1 (enExample)
CA (1) CA3198661A1 (enExample)
WO (1) WO2022081661A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12605377B2 (en) 2020-10-13 2026-04-21 Endeavor Biomedicines, Inc. Methods of treating fibrosis
CN116349204A (zh) 2020-10-13 2023-06-27 奋进生物医药公司 治疗纤维化的方法
AU2024230449A1 (en) * 2023-02-28 2025-09-11 Endeavor Biomedicines, Inc. Methods of treating fibrosis
US12447148B2 (en) 2024-03-05 2025-10-21 Endeavor Biomedicines, Inc. Methods of improving lung function
WO2025189041A1 (en) * 2024-03-07 2025-09-12 Endeavor Biomedicines, Inc. Methods of treating fibrosis
WO2025242197A1 (zh) * 2024-05-24 2025-11-27 成都思倍博医药科技有限公司 氘代的Hedgehog通路SMO受体抑制剂

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN148482B (enExample) 1977-06-03 1981-03-07 Pfizer
ZA97288B (en) 1996-01-15 1998-07-14 Janssen Pharmaceutica Nv Angiogenesis inhibiting pyridazinamines
CA2326654C (en) 1998-04-09 2010-11-09 Johns Hopkins University School Of Medicine Use of steroidal alkaloid derivatives as inhibitors of hedgehog signaling pathways
ES2233383T3 (es) 1999-06-08 2005-06-16 Lorantis Limited Utilizacion terapeutica de un ihibidor de la via de señalizacion hedgehog.
AU2003231032B2 (en) 2002-04-22 2008-07-10 Johns Hopkins University School Of Medicine Modulators of hedgehog signaling pathways, compositions and uses related thereto
AU2003265853A1 (en) 2002-08-29 2004-03-19 Curis, Inc. Hedgehog antagonists, methods and uses related thereto
US8067608B2 (en) 2003-09-29 2011-11-29 The Johns Hopkins University Hedgehog pathway antagonists
WO2005080378A1 (ja) 2004-02-24 2005-09-01 Mitsubishi Pharma Corporation 縮合ピリダジン誘導体
WO2006004589A2 (en) 2004-05-08 2006-01-12 Neurogen Corporation 3-aryl-5,6-disubstituted pyridazines
KR20200019263A (ko) 2004-09-02 2020-02-21 제넨테크, 인크. 헤지호그 신호전달에 대한 피리딜 억제제
EP1900731A1 (de) 2006-09-07 2008-03-19 Bayer Schering Pharma Aktiengesellschaft N-(1-Phthalazin-1-yl-piperidin-4-yl)-amide als EP2-Rezeptor Modulatoren
EP2137162B1 (en) 2007-03-15 2018-08-01 Novartis AG Organic compounds and their uses
ES2505091T3 (es) 2007-06-25 2014-10-09 Amgen Inc. Compuestos, composiciones y métodos de uso de ftalazina
US8222251B2 (en) 2007-09-07 2012-07-17 Amgen Inc. Pyridopyridazine compounds, compositions and methods of use
US7981892B2 (en) 2008-04-29 2011-07-19 Eli Lilly And Company Disubstituted phthalazine hedgehog pathway antagonists
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
CA2732101C (en) 2008-08-04 2013-09-17 Amgen Inc. Aurora kinase modulators and methods of use
PE20110433A1 (es) 2008-11-03 2011-07-09 Lilly Co Eli Antagonistas de la via hedgehog de ftalazina disustituida
JP5518088B2 (ja) 2008-11-17 2014-06-11 イーライ リリー アンド カンパニー 四置換ピリダジンヘッジホッグ経路アンタゴニスト
PL2358698T3 (pl) 2008-11-17 2013-01-31 Lilly Co Eli Czteropodstawione pirydazyny jako antagoniści szlaku HEDGEHOG
AR077014A1 (es) * 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer
US20110183948A1 (en) 2010-01-15 2011-07-28 Infinity Pharmaceuticals, Inc. Treatment of fibrotic conditions using hedgehog inhibitors
GB201309508D0 (en) * 2013-05-28 2013-07-10 Redx Pharma Ltd Compounds
WO2015120257A2 (en) * 2014-02-06 2015-08-13 The Brigham And Women's Hospital, Inc. Uses of gli1 in detecting tissue fibrosis
GB2528298A (en) * 2014-07-16 2016-01-20 Redx Pharma Plc Compounds
JP2018535238A (ja) 2015-11-30 2018-11-29 イグナイタ インコーポレイテッド 局所製剤
CN109890390A (zh) * 2016-11-04 2019-06-14 上海瑛派药业有限公司 Hedgehog通路抑制剂在治疗纤维化疾病中的应用
US11154541B2 (en) 2018-06-29 2021-10-26 The Trustees Of Indiana University Methods for treating aortic valve stenosis with a hedgehog pathway inhibitor
CN112449602A (zh) * 2018-07-19 2021-03-05 瓦里安医疗系统公司 超高剂量率辐射和治疗剂的使用方法
CN116349204A (zh) * 2020-10-13 2023-06-27 奋进生物医药公司 治疗纤维化的方法
US12605377B2 (en) 2020-10-13 2026-04-21 Endeavor Biomedicines, Inc. Methods of treating fibrosis
AU2024230449A1 (en) 2023-02-28 2025-09-11 Endeavor Biomedicines, Inc. Methods of treating fibrosis

Similar Documents

Publication Publication Date Title
JP6141958B2 (ja) 増殖性疾患の治療のための併用療法（ベムラフェニブ及びｍｄｍ２阻害剤）
KR102634247B1 (ko) 다발성 골수종을 치료하기 위한 약물 병용물
JP6091593B2 (ja) 慢性閉塞性肺疾患の急性増悪の治療におけるピラゾール誘導体の使用
KR20140022048A (ko) 선택된 환자에서의 피르페니돈 및 항-섬유성 치료제
JP2019515884A5 (enExample)
EA020193B1 (ru) Комбинации, включающие метотрексат и ингибиторы дигидрооротатдегидрогеназы (dhodh)
JP2004521134A5 (enExample)
EP1358177B1 (en) Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance
JP6145946B2 (ja) 併用ａｌｓ療法
JP2019520344A5 (enExample)
JP2019533660A5 (enExample)
JP2026510290A (ja) 線維症を処置する方法
Li et al. A comparative study of esketamine-propofol and sufentanil-propofol for analgesia and sedation during breast minimally invasive rotary resection with local anesthesia: a randomized double-blind clinical trial
JP2023528896A5 (enExample)
JP2013536206A5 (enExample)
JP2019531286A5 (enExample)
JP2022518788A (ja) オピオイド鎮痛耐性を治療するためのｍＧｌｕＲ５アンタゴニストの使用
JP5862897B2 (ja) 腎機能障害の予防又は治療に用いる医薬
JP2009510142A (ja) 急性および慢性肺障害の処置のための可溶性グアニル酸シクラーゼ活性化剤の使用
JP2020050624A (ja) 線維症治療用医薬組成物
JP2021519285A (ja) ダブラフェニブ、トラメチニブ及びｅｒｋ阻害剤を含む医薬品の三重の組合せ
CN119837862A (zh) 玛沃谷兰在减少酒精使用或在预防复用酒精中的用途
JP2003513888A (ja) 神経疾患治療用医薬品
JP2024523558A5 (enExample)
US20240207274A1 (en) Larotrectinib and moderate CYP3A4 inducer